Company / SG&A Expense
Anika Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$49.1M
FY2025
5-year range
$35.0M / $60.1M
FY2021-FY2025
Trend
-11.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $60M in FY2022 to $49M in FY2025.
Based on SEC 10-K filings.
$49M in FY2025 with a 5-year CAGR of +7.4%.
Improved from $60M to $49M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -6.5%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Anika Therapeutics, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, sg&a expense decreased 11.6% year-over-year.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $49.1M | -11.6% |
| FY2024 | $55.6M | -7.3% |
| FY2023 | $59.9M | -0.2% |
| FY2022 | $60.1M | +71.9% |
| FY2021 | $35.0M | +1.8% |
| FY2020 | $34.3M | +59.4% |
| FY2019 | $21.5M | +19.6% |
| FY2018 | $18.0M | +21.5% |
| FY2017 | $14.8M | -1.7% |
| FY2016 | $15.1M | +16.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026